FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileVeraxa Biotech Holding AG
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
VRXA
Veraxa Biotech Holding AG Stock AnalysisComprehensive stock analysis for Veraxa Biotech Holding AG (VRXA) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisVRXA
VRXA
Veraxa Biotech Holding AG
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
VRXA
  1. Home
  2. Stocks
  3. Veraxa Biotech Holding AG

Veraxa Biotech Holding AG

🇺🇸VRXA•NASDAQ

Veraxa Biotech Holding AG

🇺🇸VRXA•NASDAQ
Market cap
$145.65M

Your view on VRXA

Mkt Cap
$145.65M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Veraxa Biotech Holding AG

Industry
Biotechnology
Sector
Healthcare
CEO
Christoph Antz
Headquarters
Im Neuenheimer Feld 584, Heidelberg, ZH, DE
Industry
Biotechnology
Sector
Healthcare
CEO
Christoph Antz
Headquarters
Im Neuenheimer Feld 584, Heidelberg, ZH, DE
Description

Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp., focusing on developing next-generation cancer therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers. [64, 65]

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Veraxa Biotech Holding AG. Starting points for Veraxa Biotech Holding AG: EPS -$0.58, beta 0.26 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Veraxa Biotech Holding AG. Trailing twelve-month EPS for Veraxa Biotech Holding AG stands at -$0.58. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Veraxa Biotech Holding AG. Veraxa Biotech Holding AG has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold VRXA12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
NTI.AXNeurotech International LimitedHealthcareASX—
NTIINeurobiological Technologies, Inc.HealthcareOTC$2,702
NTLAIntellia Therapeutics, Inc.HealthcareNASDAQ$1.4B
NTRBNutriband Inc.HealthcareNASDAQ$58.6M
NTRBWNutriband Inc.HealthcareNASDAQ$76.8M
NTRRNeutra Corp.HealthcareOTC$291,790
NURPFNeuren Pharmaceuticals LimitedHealthcareOTC$1.1B
NUVBNuvation Bio Inc.HealthcareNYSE$1.3B
NUZ.AXNeurizon Therapeutics LimitedHealthcareASX—
NVAXNovavax, Inc.HealthcareNASDAQ$1.3B
NVCTNuvectis Pharma, Inc.HealthcareNASDAQ$697.8M
NWBONorthwest Biotherapeutics, Inc.HealthcareOTC$359.4M
Ownership & News

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Veraxa Biotech Holding AG executives and directors. Shares of Veraxa Biotech Holding AG have traded between $1.70 and $27.36 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Veraxa Biotech Holding AG. Coverage tracks Veraxa Biotech Holding AG within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Veraxa Biotech Holding AG.

VRXA AnalysisWeak
Past
1
Growth
0
Health
0
Profit
0
Value
0

News

Latest Market News